Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.47391/JPMA.5732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IUPHAR review: Drug Repurposing in Schizophrenia - An Updated Review of Clinical Trials.
Pharmacol Res
January 2025
Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK. Electronic address:
There is an urgent need for mechanistically novel and more efficacious treatments for schizophrenia, especially those targeting negative and cognitive symptoms with a more favorable side-effect profile. Drug repurposing-the process of identifying new therapeutic uses for already approved compounds-offers a promising approach to overcoming the lengthy, costly, and high-risk process of traditional CNS drug discovery. This review aims to update our previous findings on the clinical drug repurposing pipeline in schizophrenia.
View Article and Find Full Text PDFXanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes.
Pharmacopsychiatry
January 2025
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson-Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo.
View Article and Find Full Text PDFXanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy), a Food and Drug Administration approved treatment for schizophrenia in adults.
View Article and Find Full Text PDFA Clinically Oriented Review of New Antipsychotics for Schizophrenia.
Neuropsychiatr Dis Treat
December 2024
Department of Medicine and Surgery, Kore University of Enna, Enna (EN), Italy.
Article Synopsis
- Current antipsychotics mainly target dopamine but often fail to address the complexity of schizophrenia and can cause significant side effects, highlighting a need for new treatments.
- Recent research is focusing on non-dopaminergic antipsychotics, such as muscarinic agonists and 5-HT2A antagonists, to offer better therapeutic options for schizophrenia.
- While new drugs like xanomeline-trospium have been approved, others like bitopertin and pimavanserin were halted in development, emphasizing the need for cautious evaluation of their efficacy and safety.
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis.
Eur Neuropsychopharmacol
December 2024
SCIENCES Lab, Department of Psychiatry, University of Ottawa, Ottawa, Canada; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; Department of Mental Health, The Ottawa Hospital, Ottawa, Canada; Ottawa Hospital Research Institute: Clinical Epidemiology Program, University of Ottawa, Ottawa, Canada; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada. Electronic address:
The United States Food and Drug Administration approved xanomeline-trospium combination for schizophrenia on September-26-2024. We conducted a PRISMA 2020-compliant systematic review with random-effects meta-analysis on the efficacy and safety of xanomeline-trospium in randomized controlled trials in patients with schizophrenia (MEDLINE, EMBASE, Cochrane, PsycINFO, October-01-2024). Co-primary outcomes were Positive And Negative Syndrome Scale (PANSS) total score (standardized mean difference=SMD), and all-cause discontinuation (risk ratio=RR).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!